BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoes JN, Jacobs JWG, Verstappen SMM, Bijlsma JWJ, Van der Heijden GJMG. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Annals of the Rheumatic Diseases 2009;68:1833-8. [DOI: 10.1136/ard.2008.100008] [Cited by in Crossref: 130] [Cited by in F6Publishing: 118] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Henrique da Mota LM, Afonso Cruz B, Viegas Brenol C, Alves Pereira I, Rezende-fronza LS, Barros Bertolo M, Carioca Freitas MV, da Silva NA, Louzada-junior P, Neubarth Giorgio RD, Corrêa Lima RA, Marques Bernardo W, Castelar Pinheiro GDR. Diretrizes para o tratamento da artrite reumatoide. Revista Brasileira de Reumatologia 2013;53:158-83. [DOI: 10.1590/s0482-50042013000200004] [Cited by in Crossref: 20] [Article Influence: 2.2] [Reference Citation Analysis]
2 Morimoto N, Nagahama K, Oyama S, Tsuura Y, Fukutomi T, Terai A, Tanabe M, Otani M, Shioji S, Hirasawa S, Aki S, Aoyagi M, Tanaka H. Immunotactoid glomerulonephritis in a patient with cold agglutinins: causal association or mere coincidence? CEN Case Rep 2021. [PMID: 33847918 DOI: 10.1007/s13730-021-00600-2] [Reference Citation Analysis]
3 Spies CM, Strehl C, van der Goes MC, Bijlsma JW, Buttgereit F. Glucocorticoids. Best Pract Res Clin Rheumatol 2011;25:891-900. [PMID: 22265268 DOI: 10.1016/j.berh.2011.11.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
4 Georgakopoulou EA, Scully C. Systemic use of non-biologic corticosteroids in orofacial diseases. Oral Dis 2014;20:127-35. [PMID: 23746234 DOI: 10.1111/odi.12132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Sendrasoa FA, Ranaivo IM, Raherivelo AJ, Rapelanoro Rabenja F, Ramarozatovo LS. Adverse Effects of Long-Term Oral Corticosteroids in the Department of Dermatology, Antananarivo, Madagascar. Clin Cosmet Investig Dermatol 2021;14:1337-41. [PMID: 34594123 DOI: 10.2147/CCID.S332201] [Reference Citation Analysis]
6 Chávez-Mendoza CA, Niño-Cruz JA, Correa-Rotter R, Uribe-Uribe NO, Mejía-Vilet JM. Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis. Kidney Int Rep 2019;4:40-7. [PMID: 30596167 DOI: 10.1016/j.ekir.2018.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Blanco-Morales EA, Bravo-Ferrer Acosta JM, Rubio Romero E, Gil González E, Gantes Pedraza MÁ. [Glucocorticoids in rheumatoid arthritis: almost always or hardly ever?]. Reumatol Clin 2011;7:407-11. [PMID: 22078702 DOI: 10.1016/j.reuma.2011.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Mazzantini M, Torre C, Miccoli M, Baggiani A, Talarico R, Bombardieri S, Di Munno O. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012;39:552-557. [PMID: 22247343 DOI: 10.3899/jrheum.110851] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
9 Mueller RB, Reshiti N, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, Schiff M, Spaeth M, von Kempis J; SCQM physicians. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). Clin Rheumatol 2017;36:59-66. [PMID: 27838788 DOI: 10.1007/s10067-016-3468-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Mainguy-Seers S, Lavoie JP. Glucocorticoid treatment in horses with asthma: A narrative review. J Vet Intern Med 2021;35:2045-57. [PMID: 34085342 DOI: 10.1111/jvim.16189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Strehl C, Buttgereit F. [Long-term glucocorticoid therapy : Is there a safe dosage?]. Internist (Berl) 2016;57:934-9. [PMID: 27351788 DOI: 10.1007/s00108-016-0098-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Fortunet C, Pers Y, Lambert J, Godfrin-valnet M, Constant E, Devilliers H, Gaudin P, Jorgensen C, Prades BP, Wendling D, Maillefert JF. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatology 2015;54:672-7. [DOI: 10.1093/rheumatology/keu339] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
13 Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open 2020;6:e000536. [PMID: 31958273 DOI: 10.1136/rmdopen-2017-000536] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
14 Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011;13:R139. [PMID: 21884589 DOI: 10.1186/ar3453] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 8.9] [Reference Citation Analysis]
15 Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 2010;10:605-11. [PMID: 20651747 DOI: 10.1038/nri2804] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
16 Navaneethan U, Venkatesh PG, Shen B. Risks and benefits of ileal pouch–anal anastomosis for ulcerative colitis. Therapy 2011;8:83-99. [DOI: 10.2217/thy.10.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 Okayasu M, Ogata H, Yoshiyama Y. Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. J Mark Access Health Policy 2019;7:1565889. [PMID: 30719244 DOI: 10.1080/20016689.2019.1565889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA. Burden of systemic glucocorticoid-related complications in severe asthma. Curr Med Res Opin 2017;33:57-65. [PMID: 27627132 DOI: 10.1080/03007995.2016.1233101] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
19 Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142. [PMID: 30518410 DOI: 10.1186/s40425-018-0461-4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis]
20 Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095-1103. [PMID: 24641622 DOI: 10.1111/apt.12712] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
21 Cheah JTL, Robson JC, Black RJ, Goodman SM, Lester S, Mackie SL, Hill CL. The patient's perspective of the adverse effects of glucocorticoid use: A systematic review of quantitative and qualitative studies. From an OMERACT working group. Semin Arthritis Rheum 2020;50:996-1005. [PMID: 32911291 DOI: 10.1016/j.semarthrit.2020.06.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 García-Magallón B, Silva-Fernández L, Andreu-Sánchez JL. Update on the use of steroids in rheumatoid arthritis. Reumatol Clin 2013;9:297-302. [PMID: 23726772 DOI: 10.1016/j.reuma.2013.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
23 Nas K, Kiliç E, Çevik R, Bodur H, Ataman Ş, Ayhan F, Akgül Ö, Akinci A, Altay Z, Çapkın E, Dağli AZ, Duruöz T, Gürer G, Göğüş F, Garip Y, Kaçar C, Kamanli A, Kaptanoğlu E, Kaya T, Kocabaş H, Özdemirel EA, Özel S, Sezer İ, Sunar İ, Yilmaz G. Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions. Arch Rheumatol 2018;33:108-27. [PMID: 30207576 DOI: 10.5606/ArchRheumatol.2018.6946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol 2020;16:481-95. [DOI: 10.1038/s41584-020-0458-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
25 Bunu DM, Timofte CE, Ciocoiu M, Floria M, Tarniceriu CC, Barboi OB, Tanase DM. Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies. Gastroenterol Res Pract 2019;2019:3012509. [PMID: 30733802 DOI: 10.1155/2019/3012509] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 8.7] [Reference Citation Analysis]
26 Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis 2013;19:1872-9. [PMID: 23714676 DOI: 10.1097/MIB.0b013e3182874065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
27 Sinh P, Cross R. Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1107-15. [PMID: 32978937 DOI: 10.1093/ibd/izaa258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 van Raalte DH, Brands M, van der Zijl NJ, Muskiet MH, Pouwels PJ, Ackermans MT, Sauerwein HP, Serlie MJ, Diamant M. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia. 2011;54:2103-2112. [PMID: 21562755 DOI: 10.1007/s00125-011-2174-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
29 Plaza G, Durio E, Herráiz C, Rivera T, García-Berrocal JR; Asociación Madrileña de ORL. [Consensus on diagnosis and treatment of sudden hearing loss. Asociación Madrileña de ORL]. Acta Otorrinolaringol Esp 2011;62:144-57. [PMID: 21112580 DOI: 10.1016/j.otorri.2010.09.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
30 Cross RK. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1689-701. [DOI: 10.1097/mib.0000000000001261] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
31 Zhang YP, Gong Y, Zeng QY, Hou ZD, Xiao ZY. A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. BMJ Open 2015;5:e006957. [PMID: 26041488 DOI: 10.1136/bmjopen-2014-006957] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
32 Berti A, Dejaco C. Update on the epidemiology, risk factors, and outcomes of systemic vasculitides. Best Practice & Research Clinical Rheumatology 2018;32:271-94. [DOI: 10.1016/j.berh.2018.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
33 Liew DF, Owen CE, Buchanan RR. Prescribing for polymyalgia rheumatica. Aust Prescr 2018;41:14-9. [PMID: 29507455 DOI: 10.18773/austprescr.2018.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford) 2011;50:1982-90. [PMID: 21393338 DOI: 10.1093/rheumatology/ker017] [Cited by in Crossref: 137] [Cited by in F6Publishing: 123] [Article Influence: 12.5] [Reference Citation Analysis]
35 Gaujoux-viala C, Gossec L. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations: Glucocorticoids in RA recommendations. Ann N Y Acad Sci 2014;1318:32-40. [DOI: 10.1111/nyas.12452] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
36 He Y, Shi J, Yi W, Ren X, Gao X, Li J, Wu N, Weaver K, Xie Q, Khoo SK, Yang T, Huang X, Melcher K, Xu HE. Discovery of a highly potent glucocorticoid for asthma treatment. Cell Discov 2015;1:15035. [PMID: 27066265 DOI: 10.1038/celldisc.2015.35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 McHarg M, Young L, Kesav N, Yakin M, Sen HN, Kodati S. Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study. J Ophthalmic Inflamm Infect 2022;12:3. [PMID: 34982279 DOI: 10.1186/s12348-021-00281-z] [Reference Citation Analysis]
38 Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol 2015;136:1488-95. [PMID: 26414880 DOI: 10.1016/j.jaci.2015.07.046] [Cited by in Crossref: 83] [Cited by in F6Publishing: 89] [Article Influence: 11.9] [Reference Citation Analysis]
39 Matsubayashi H, Ishiwatari H, Imai K, Kishida Y, Ito S, Hotta K, Yabuuchi Y, Yoshida M, Kakushima N, Takizawa K, Kawata N, Ono H. Steroid Therapy and Steroid Response in Autoimmune Pancreatitis. Int J Mol Sci. 2019;21. [PMID: 31905944 DOI: 10.3390/ijms21010257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Pereira Filho MV, Stéfani KC, Ferreira GF, Nogueira MP. Risk Factors Associated With Foot and Ankle Insufficiency Fractures in Postmenopausal Sedentary Women. Foot Ankle Int 2021;42:482-7. [PMID: 33203230 DOI: 10.1177/1071100720969654] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Hua L, Du H, Ying M, Wu H, Fan J, Shi X. Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial. Medicine (Baltimore) 2020;99:e20824. [PMID: 32629668 DOI: 10.1097/MD.0000000000020824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Helliwell T, Hider SL, Barraclough K, Dasgupta B, Mallen CD. Diagnosis and management of polymyalgia rheumatica. Br J Gen Pract 2012;62:275-6. [PMID: 22546589 DOI: 10.3399/bjgp12X641636] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
43 Trampisch US, Krause D, Trampisch HJ, Klaassen-Mielke R, Baraliakos X, Braun J. Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. Trials 2014;15:344. [PMID: 25181946 DOI: 10.1186/1745-6215-15-344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
44 Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord 2019;33:22-32. [PMID: 31136907 DOI: 10.1016/j.msard.2019.05.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
45 Myasoedova E, Matteson EL, Talley NJ, Crowson CS. Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study. J Rheumatol 2012;39:1355-62. [PMID: 22467929 DOI: 10.3899/jrheum.111311] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
46 Targownik LE, Nugent Z, Singh H, Bernstein CN. Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:622-30. [DOI: 10.1097/mib.0000000000000008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 4.4] [Reference Citation Analysis]
47 Gaujoux-viala C, Gossec L, Cantagrel A, Dougados M, Fautrel B, Mariette X, Nataf H, Saraux A, Trope S, Combe B. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spine 2014;81:287-97. [DOI: 10.1016/j.jbspin.2014.05.002] [Cited by in Crossref: 94] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
48 Owen CE, Yates M, Twohig H, Muller S, Neill LM, Harrison E, Shea B, Simon LS, Hill CL, Mackie SL. Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group. J Rheumatol 2019;46:1360-4. [DOI: 10.3899/jrheum.181050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D. European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. [PMID: 26644232 DOI: 10.1136/annrheumdis-2015-208337] [Cited by in Crossref: 568] [Cited by in F6Publishing: 472] [Article Influence: 81.1] [Reference Citation Analysis]
50 Hijaz NM, Septer SS, Degaetano J, Attard TM. Clinical outcome of pediatric collagenous gastritis: Case series and review of literature. World J Gastroenterol 2013; 19(9): 1478-1484 [PMID: 23538318 DOI: 10.3748/wjg.v19.i9.1478] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
51 Kissin EY. The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy. Clin Ther 2014;36:1114-6. [PMID: 24996488 DOI: 10.1016/j.clinthera.2014.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Yang YH, Morand E, Leech M. Annexin A1: potential for glucocorticoid sparing in RA. Nat Rev Rheumatol 2013;9:595-603. [PMID: 23958797 DOI: 10.1038/nrrheum.2013.126] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
53 Park JK, Shin K, Kang E, Ha Y, Lee YJ, Lee KH, Lee EY, Song YW, Choi Y, Lee EB. Efficacy and Tolerability of GCSB-5 for Hand Osteoarthritis: A Randomized, Controlled Trial. Clinical Therapeutics 2016;38:1858-1868.e2. [DOI: 10.1016/j.clinthera.2016.06.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
54 Collinson N, Tuckwell K, Habeck F, Chapman M, Klearman M, Stone JH. Development and implementation of a double-blind corticosteroid-tapering regimen for a clinical trial. Int J Rheumatol 2015;2015:589841. [PMID: 25878667 DOI: 10.1155/2015/589841] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
55 Chen H, Zhou R, Pang J, Guo Y, Chen J, Kang Y, Duan M, Hou T. Molecular View on the Dissociation Pathways and Transactivation Regulation Mechanism of Nonsteroidal GR Ligands. J Chem Inf Model 2021. [PMID: 34506144 DOI: 10.1021/acs.jcim.1c00150] [Reference Citation Analysis]
56 Owen CE, McMaster C, Liew DFL, Leung JL, Scott AM, Buchanan RRC. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica. Int J Rheum Dis 2021;24:56-62. [PMID: 33043616 DOI: 10.1111/1756-185X.14000] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Sivaraman P, Cohen SB. Malignancy and Janus Kinase Inhibition. Rheum Dis Clin North Am 2017;43:79-93. [PMID: 27890175 DOI: 10.1016/j.rdc.2016.09.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
58 Jones G, Hall S, Bird P, Littlejohn G, Tymms K, Youssef P, Chung E, Barrett R, Button P. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Int J Rheum Dis 2018;21:1581-90. [PMID: 29205926 DOI: 10.1111/1756-185X.13243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
59 Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH. Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. Clin J Am Soc Nephrol 2016;11:386-94. [PMID: 26912551 DOI: 10.2215/CJN.07110615] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
60 Kebaish KJ, Galivanche AR, Varthi AG, Ottesen TD, Rubin LE, Grauer JN. Long-term Corticosteroid Use Independently Correlates With Complications After Posterior Lumbar Spine Surgery. Orthopedics 2021;44:172-9. [PMID: 34039214 DOI: 10.3928/01477447-20210416-01] [Reference Citation Analysis]
61 Valdes LM, Sobrin L. Uveitis Therapy: The Corticosteroid Options. Drugs 2020;80:765-73. [PMID: 32350761 DOI: 10.1007/s40265-020-01314-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
62 Omair MA, Omair MA, Halabi H. Survey on management strategies of rheumatoid arthritis in Saudi Arabia: a Saudi Society for Rheumatology Initiative. Int J Rheum Dis 2017;20:1185-92. [PMID: 26354409 DOI: 10.1111/1756-185X.12735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Hoon E, Ruediger C, Gill TK, Black RJ, Hill CL. A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis. Open Access Rheumatol 2019;11:189-98. [PMID: 31695526 DOI: 10.2147/OARRR.S213964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
64 Björkman MP, Pilvi TK, Kekkonen RA, Korpela R, Tilvis RS. Similar effects of leucine rich and regular dairy products on muscle mass and functions of older polymyalgia rheumatica patients: a randomized crossover trial. J Nutr Health Aging 2011;15:462-7. [PMID: 21623468 DOI: 10.1007/s12603-010-0276-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
65 Gisondi P, Altomare G, Ayala F, Conti A, Dapavo P, De Simone C, Foti C, Idolazzi L, Lubrano E, Malara G, Marchesoni A, Olivieri I, Parodi A, Peris K, Piaserico S, Salvarani C, Scarpa R, Girolomoni G. Consensus on the management of patients with psoriatic arthritis in a dermatology setting. J Eur Acad Dermatol Venereol 2018;32:515-28. [PMID: 29220551 DOI: 10.1111/jdv.14741] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
66 Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort. American Journal of Gastroenterology 2018;113:384-95. [DOI: 10.1038/ajg.2017.482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
67 Jackson RD. Topical Corticosteroids and Glucocorticoid-Induced Osteoporosis-Cumulative Dose and Duration Matter. JAMA Dermatol 2021;157:269-70. [PMID: 33471024 DOI: 10.1001/jamadermatol.2020.4967] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Mohney N, Williamson CA, Rothman E, Ball R, Sheehan KM, Pandey AS, Fletcher JJ, Jacobs TL, Thompson BG, Rajajee V. A Propensity Score Analysis of the Impact of Dexamethasone Use on Delayed Cerebral Ischemia and Poor Functional Outcomes After Subarachnoid Hemorrhage. World Neurosurg 2018;109:e655-61. [PMID: 29061461 DOI: 10.1016/j.wneu.2017.10.051] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
69 Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract 2013;63:e361-6. [PMID: 23643235 DOI: 10.3399/bjgp13X667231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
70 Della Corte C, Sartorelli MR, Sindoni CD, Girolami E, Giovannelli L, Comparcola D, Nobili V. Autoimmune hepatitis in children: an overview of the disease focusing on current therapies. European Journal of Gastroenterology & Hepatology 2012;24:739-46. [DOI: 10.1097/meg.0b013e328353750c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
71 Manzo C, Nizama-Via A, Milchert M, Isetta M, Castagna A, Natale M, Serra-Mestres J. Depression and depressive symptoms in patients with polymyalgia rheumatica: discussion points, grey areas and unmet needs emerging from a systematic review of published literature. Reumatologia 2020;58:381-9. [PMID: 33456081 DOI: 10.5114/reum.2020.102003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Benvenuto LJ, Anderson MR, Arcasoy SM. New frontiers in immunosuppression. J Thorac Dis 2018;10:3141-55. [PMID: 29997983 DOI: 10.21037/jtd.2018.04.79] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
73 Whitehouse MW. Anti-inflammatory glucocorticoid drugs: reflections after 60 years. Inflammopharmacology 2011;19:1-19. [PMID: 21072600 DOI: 10.1007/s10787-010-0056-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
74 Clarke L, Kirwan J. Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012;4:159-66. [PMID: 22850902 DOI: 10.1177/1759720X12441274] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
75 Triantafillidis JK, Merikas E, Gikas A. Psychological factors and stress in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2013;7:225-238. [PMID: 23445232 DOI: 10.1586/egh.13.4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
76 Hoes JN, Jacobs JWG, Bijlsma JWJ. Glucocorticoids are forever? Rheumatology 2011;50:1940-1. [DOI: 10.1093/rheumatology/ker141] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
77 Liu L, Guo W, Liang X. Move to Nano-Arthrology: Targeted Stimuli-Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis. Biotechnol J 2019;14:1800024. [DOI: 10.1002/biot.201800024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
78 Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol 2013;27:1022-5. [PMID: 22830601 DOI: 10.1111/j.1468-3083.2012.04656.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
79 Fritz D, Voortman M, van de Beek D, Drent M, Brouwer MC. Many faces of neurosarcoidosis: from chronic meningitis to myelopathy. Current Opinion in Pulmonary Medicine 2017;23:439-46. [DOI: 10.1097/mcp.0000000000000401] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
80 Best JH, Kong AM, Lenhart GM, Sarsour K, Stott-Miller M, Hwang Y. Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis. J Rheumatol 2018;45:320-8. [PMID: 29335343 DOI: 10.3899/jrheum.170418] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
81 Guijarro IM, Garcés M, Andrés-Benito P, Marín B, Otero A, Barrio T, Carmona M, Ferrer I, Badiola JJ, Monzón M. Assessment of Glial Activation Response in the Progress of Natural Scrapie after Chronic Dexamethasone Treatment. Int J Mol Sci 2020;21:E3231. [PMID: 32370224 DOI: 10.3390/ijms21093231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
82 Burt MG, Willenberg VM, Petersons CJ, Smith MD, Ahern MJ, Stranks SN. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology 2012;51:1112-9. [DOI: 10.1093/rheumatology/kes003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
83 Regan P, Elkhalifa S, Barratt P. The systemic immunosuppressive effects of peripheral corticosteroid injections: A narrative review of the evidence in the context of COVID-19. Musculoskeletal Care 2021. [PMID: 34882956 DOI: 10.1002/msc.1603] [Reference Citation Analysis]
84 Mercieca C, Kirwan JR. The intelligent use of systemic glucocorticoids in rheumatoid arthritis. Expert Rev Clin Immunol 2014;10:143-57. [PMID: 24308837 DOI: 10.1586/1744666X.2014.864236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Krasselt M, Baerwald C. Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis. Drug Des Devel Ther 2016;10:1047-58. [PMID: 27022244 DOI: 10.2147/DDDT.S87792] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
86 Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011;70:956-960. [PMID: 21285116 DOI: 10.1136/ard.2010.144741] [Cited by in Crossref: 90] [Cited by in F6Publishing: 70] [Article Influence: 8.2] [Reference Citation Analysis]
87 Jacobs JW. Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies. Rheumatology (Oxford) 2012;51 Suppl 4:iv27-33. [PMID: 22685273 DOI: 10.1093/rheumatology/kes084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
88 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Intest Res. 2017;15:266-284. [PMID: 28670225 DOI: 10.5217/ir.2017.15.3.266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
89 Molnár A, Maihoub S, Tamás L, Szirmai Á. Intratympanically administered steroid for progressive sensorineural hearing loss in Ménière’s disease. Acta Oto-Laryngologica 2019;139:982-6. [DOI: 10.1080/00016489.2019.1658898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
90 Markmann C, Bhoj VG. On the road to eliminating long-lived plasma cells-"are we there yet?". Immunol Rev 2021;303:154-67. [PMID: 34351644 DOI: 10.1111/imr.13015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Ghazawi FM, Lim M, Dutz JP, Kirchhof MG. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. Int J Dermatol 2020;59:1043-56. [PMID: 32621284 DOI: 10.1111/ijd.15028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
92 Safy M, Jacobs J, IJff ND, Bijlsma J, van Laar JM, de Hair M; Society for Rheumatology Research Utrecht (SRU). Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Ann Rheum Dis 2017;76:1432-5. [PMID: 28450312 DOI: 10.1136/annrheumdis-2016-210647] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
93 Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier R, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favourable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7:93. [PMID: 30940209 DOI: 10.1186/s40425-019-0577-1] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 19.7] [Reference Citation Analysis]
94 Black RJ, Robson JC, Goodman SM, Hoon E, Lai LYH, Simon LS, Harrison E, Neill L, Richards P, Nelsen LM, Nebesky JM, Mackie SL, Hill CL. A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. J Rheumatol 2017;44:1754-8. [PMID: 28365575 DOI: 10.3899/jrheum.161083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
95 Gracie DJ, Guthrie EA, Hamlin PJ, Ford AC. Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. Gastroenterology. 2018;154:1635-1646.e3. [PMID: 29366841 DOI: 10.1053/j.gastro.2018.01.027] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 28.3] [Reference Citation Analysis]
96 Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review. Clinical Therapeutics 2011;33:1413-32. [DOI: 10.1016/j.clinthera.2011.09.009] [Cited by in Crossref: 124] [Cited by in F6Publishing: 115] [Article Influence: 11.3] [Reference Citation Analysis]
97 Jou E, Zhou AK, Ho JSY, Thahir A. Perioperative use of intra-articular steroids during the COVID-19 pandemic. Eur J Orthop Surg Traumatol 2021. [PMID: 34468841 DOI: 10.1007/s00590-021-03105-x] [Reference Citation Analysis]
98 Cheah JTL, Black RJ, Robson JC, Navarro-Millán IY, Young SR, Richards P, Beard S, Simon LS, Goodman SM, Mackie SL, Hill CL. Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group. J Rheumatol 2019;46:1179-82. [PMID: 30647165 DOI: 10.3899/jrheum.181082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
99 Jacobs JW, Bijlsma JW. Glucocorticoid Therapy. Kelley's Textbook of Rheumatology. Elsevier; 2013. pp. 894-916.e3. [DOI: 10.1016/b978-1-4377-1738-9.00060-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
100 Rostaing L, Malvezzi P. Steroid-Based Therapy and Risk of Infectious Complications. PLoS Med 2016;13:e1002025. [PMID: 27218466 DOI: 10.1371/journal.pmed.1002025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
101 Alwashih MA, Watson DG, Andrew R, Stimson RH, Alossaimi M, Blackburn G, Walker BR. Plasma metabolomic profile varies with glucocorticoid dose in patients with congenital adrenal hyperplasia. Sci Rep 2017;7:17092. [PMID: 29213133 DOI: 10.1038/s41598-017-17220-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
102 Bijlsma JW, van der Goes MC, Hoes JN, Jacobs JW, Buttgereit F, Kirwan J. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann N Y Acad Sci 2010;1193:123-6. [PMID: 20398017 DOI: 10.1111/j.1749-6632.2009.05342.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
103 Harris E, Tiganescu A, Tubeuf S, Mackie SL. The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy. Curr Rheumatol Rep 2015;17:513. [PMID: 25903665 DOI: 10.1007/s11926-015-0513-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
104 André V, le Goff B, Leux C, Pot-vaucel M, Maugars Y, Berthelot J. Information on glucocorticoid therapy in the main studies of biological agents. Joint Bone Spine 2011;78:478-83. [DOI: 10.1016/j.jbspin.2011.01.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
105 Endo Y, Abe Y, Kawano S, Ando T, Sakamoto K, Tamura N. The Association between Absence of Abdominal Pain and Mortality in Lower Intestinal Perforation in Patients with Autoimmune Rheumatic Diseases. Biomed Res Int 2019;2019:5381453. [PMID: 30906775 DOI: 10.1155/2019/5381453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Jothimani D, Cramp ME, Mitchell JD, Cross TJS. Treatment of autoimmune hepatitis: A review of current and evolving therapies: Treatment of autoimmune hepatitis. Journal of Gastroenterology and Hepatology 2011;26:619-27. [DOI: 10.1111/j.1440-1746.2010.06579.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
107 Strehl C, Buttgereit F. Optimized glucocorticoid therapy: Teaching old drugs new tricks. Molecular and Cellular Endocrinology 2013;380:32-40. [DOI: 10.1016/j.mce.2013.01.026] [Cited by in Crossref: 67] [Cited by in F6Publishing: 48] [Article Influence: 7.4] [Reference Citation Analysis]
108 Ou G, Bressler B, Galorport C, Lam E, Ko HH, Enns R, Telford J, Schaffer N, Lee T, Rosenfeld G. Rate of Corticosteroid-Induced Mood Changes in Patients with Inflammatory Bowel Disease: A Prospective Study. J Can Assoc Gastroenterol 2018;1:99-106. [PMID: 31294728 DOI: 10.1093/jcag/gwy023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
109 Migita K, Sasaki Y, Ishizuka N, Arai T, Kiyokawa T, Suematsu E, Yoshimura M, Kawabe Y, Matsumura R, Akagawa S, Mori S, Shirai M, Watanabe Y, Minami N, Soga T, Owan I, Ohshima S, Yoshizawa S, Matsui T, Tohma S, Bito S. Glucocorticoid Therapy and the Risk of Infection in Patients With Newly Diagnosed Autoimmune Disease. Medicine (Baltimore) 2013;92:285-93. [PMID: 23982055 DOI: 10.1097/MD.0b013e3182a72299] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
110 Cabrera N, Lega J, Kassai B, Wouters C, Kondi A, Cannizzaro E, Woerner A, Chausset A, Roethlisberger S, Jeanneret C, Aeschlimann F, Malik S, Duquesne A, Kaiser D, Higel L, Maes A, Berthet G, Hentgen V, Kone-paut I, Belot A, Hofer M. Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database. Joint Bone Spine 2019;86:343-50. [DOI: 10.1016/j.jbspin.2018.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
111 Eyigör S. Dysphagia in rheumatological disorders. World J Rheumatol 2013; 3(3): 45-50 [DOI: 10.5499/wjr.v3.i3.45] [Cited by in CrossRef: 6] [Article Influence: 0.7] [Reference Citation Analysis]
112 Gabbani T, Manetti N, Bagnoli S, Annese V. Beclomethasone dipropionate for the treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2014;3:87-96. [DOI: 10.1517/21678707.2014.968125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Lehman T, Nuruzzaman F, Taber S. Systemic Lupus Erythematosus: Etiology, Pathogenesis, Clinical Manifestations, and Management. Pediatrics in Systemic Autoimmune Diseases. Elsevier; 2016. pp. 173-89. [DOI: 10.1016/b978-0-444-63596-9.00008-6] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
114 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
115 Einarsdottir MJ, Ekman P, Trimpou P, Olsson DS, Johannsson G, Ragnarsson O. High prescription rate of oral glucocorticoids in children and adults: A retrospective cohort study from Western Sweden. Clin Endocrinol (Oxf) 2020;92:21-8. [PMID: 31631358 DOI: 10.1111/cen.14114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Gaujoux-viala C, Gossec L, Cantagrel A, Dougados M, Fautrel B, Mariette X, Nataf H, Saraux A, Trope S, Combe B. Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. Revue du Rhumatisme 2014;81:303-12. [DOI: 10.1016/j.rhum.2014.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
117 Verhoeven MM, de Hair MJ, Tekstra J, Bijlsma JW, van Laar JM, Pethoe-Schramm A, Borm ME, Ter Borg EJ, Linn-Rasker SP, Teitsma XM, Lafeber FP, Jacobs JW, Welsing PM. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. Ann Rheum Dis 2019;78:1333-8. [PMID: 31196844 DOI: 10.1136/annrheumdis-2019-215304] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
118 Krasselt M, Baerwald C. The current relevance and use of prednisone in rheumatoid arthritis. Expert Review of Clinical Immunology 2014;10:557-71. [DOI: 10.1586/1744666x.2014.904746] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
119 Hoes JN, Jacobs JW, Buttgereit F, Bijlsma JW. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693-702. [PMID: 21119718 DOI: 10.1038/nrrheum.2010.179] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 7.0] [Reference Citation Analysis]
120 Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975. [PMID: 20444750 DOI: 10.1136/ard.2009.126532] [Cited by in Crossref: 1068] [Cited by in F6Publishing: 888] [Article Influence: 89.0] [Reference Citation Analysis]
121 Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, Yamanaka H. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Mod Rheumatol 2017;27:217-26. [PMID: 27414105 DOI: 10.1080/14397595.2016.1206507] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
122 He Y, Yi W, Suino-Powell K, Zhou XE, Tolbert WD, Tang X, Yang J, Yang H, Shi J, Hou L, Jiang H, Melcher K, Xu HE. Structures and mechanism for the design of highly potent glucocorticoids. Cell Res 2014;24:713-26. [PMID: 24763108 DOI: 10.1038/cr.2014.52] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
123 Dejaco C, Duftner C, Dasgupta B, Matteson EL, Schirmer M. Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly. Aging Health 2011;7:633-45. [DOI: 10.2217/ahe.11.50] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
124 Adegunsoye A, Oldham JM, Fernández Pérez ER, Hamblin M, Patel N, Tener M, Bhanot D, Robinson L, Bullick S, Chen L, Hsu S, Churpek M, Hedeker D, Montner S, Chung JH, Husain AN, Noth I, Strek ME, Vij R. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res 2017;3:00016-2017. [PMID: 28845429 DOI: 10.1183/23120541.00016-2017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
125 Roubille C, Rincheval N, Dougados M, Flipo R, Daurès J, Combe B. Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann Rheum Dis 2017;76:1797-802. [DOI: 10.1136/annrheumdis-2016-210135] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]